RHYTHM PHARMACEUTICALS INC (RYTM)
NASDAQ • Healthcare
Last close at August 11, 2026 at 20:00 UTC
Fundamentals Charts
About RHYTHM PHARMACEUTICALS INC
Rhythm Pharmaceuticals, Inc. develops and markets therapies for rare genetic obesity disorders in the biotechnology sector and trades on the NASDAQ under RYTM. Its FY2025 revenue was $189.8 million, centered on IMCIVREE, an MC4R agonist whose active compound is setmelanotide.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
RHYTHM PHARMACEUTICALS INC's Technical Indicators Summary
RYTM earns a Strong Buy grade as momentum and broad moving-average alignment point to constructive price action. Trading around $115.96, the stock is well above its short-, medium- and 200-day averages while MACD and CCI show clear bullish momentum and RSI remains supportive. ADX indicates a reasonably firm trend without extreme readings, and OBV confirms accumulation as ATR shows moderate volatility. The price sits above the classic pivot near $114.28, reinforcing the current bias, even though short-term oscillators are extended. Technical takeaway: Strong Buy.
| Indicator | Value |
|---|---|
RSI (14) | 62.59 |
Stochastic %K (14, 3, 3) | 87.24 |
CCI (20) | 135.66 |
WPR (14) | -7.68 |
Momentum (10) | 9.43 |
MFI | 70.84 |
MACD Level (12, 26) | 2.66 |
Bollinger Bands | $97.88 - $117.08 |
ATR (14) | $4.85 (4.18%) |
ADX (14) | 23.75 |
OBV | 16,046,479 |
Classic Pivot Point | $114.28 |
Fibonacci Pivot Point | $114.28 |
Simple Moving Averages | $95.33 - $109.63(5 indicators) |
Exponential Moving Averages | $100.49 - $111.36(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
Buying out of the gate leaves RYTM 3.09% above yesterday’s close (112.84). The peer group is marking time, with sector returns hovering at 0.25%. RYTM's strong AHO launch and global expansion are driving pipeline progress in rare obesity disorders.
Trading Volume
Below 10d avg (798.7K)
203.1K
vs S&P 500 Today
Outperforming Market
+2.84%
52-Week Position
Upper range
87.7%
Updated: August 12, 2026 at 16:54 UTC